Using Multi-virus Cytotoxic T-cells Following T-Cell Depleted Allogeneic HPCT for Prophylaxis Against EBV, ADV, and CMV (ACE)
A Phase I Study Of Using Multi-virus Cytotoxic T-cells Following T-cell Depleted Allogeneic Hematopoietic Progenitor Cell Transplantation For Prophylaxis Against Specific Pathogens- Epstein Barr Virus, Adenovirus, And Cytomegalovirus (ACE)
Sponsor: Medical College of Wisconsin
Listed as NCT01535885, this PHASE1 trial focuses on Adenovirus and Cytomegalovirus Infections and remains completed. Sponsored by Medical College of Wisconsin, it has been updated 10 times since 2012, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Nov 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Nov 2021 [monthly]
Completed PHASE1
-
Nov 2019 — Jan 2021 [monthly]
Completed PHASE1
Status: Recruiting → Completed
▶ Show 5 earlier versions
-
Aug 2019 — Nov 2019 [monthly]
Recruiting PHASE1
-
Jul 2018 — Aug 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE1
-
Feb 2017 — Jun 2018 [monthly]
Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE1
First recorded
Feb 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Medical College of Wisconsin
For direct contact, visit the study record on ClinicalTrials.gov .